יחס שווי פעילות לרווח לפני ריבית, מסים ופחת TriSalus Corp (TLSI)
The price history of the Separate EV/EBITDA for TriSalus Life Sciences (TLSI), which develops methods for combating gastrointestinal tumors, is 0.00. High demand for unique catheters strengthens the company's position in negotiations with clinics. Business resilience is ensured by the inelasticity of medical services relative to GDP, while the diversification of developments across different organs minimizes investment risks during the clinical trial stage.
פילוחי מדדים ואנליטיקה של חברת trisaluslifesci.com (TLSI)
The development of targeted drug delivery systems for liver and pancreatic tumors by TriSalus Life Sciences (TLSI) is reflected in the changes to its EV/EBITDA ratio. This metric compares the total enterprise value, including net debt, with operating profit before interest, taxes, depreciation, and amortization. The current value of 0.00 allows for a real-time assessment of asset value, stripped of the impact of debt load. Such an approach is critical for analyzing capital-intensive biotech companies during clinical trial periods.
